SOURCE-LINKED STUDY SUMMARY
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Full paper summarizedQuality not appraised
- What was studied
- BELIEVE, a randomized phase 2 trial, tested bimagrumab and semaglutide alone or combined for obesity. Common adverse events included gastrointestinal symptoms, muscle spasms and acne.
- Who / model studied
- 507 adults with obesity, or overweight with complications, without diabetes; nine treatment groups.
- Studied dose & schedule
- 48 weeks: bimagrumab 10 or 30 mg/kg intravenously every 12 weeks after loading; semaglutide 1.0 or 2.4 mg subcutaneously weekly; combinations or placebo.
- What the study found
- At 48 weeks, high-dose combination versus semaglutide 2.4 mg: weight −17.8 versus −14.2 kg; fat mass −15.6 versus −9.6 kg; DXA lean mass −1.3 versus −3.9 kg (treatment-regimen estimates).
- Limitations & context
- Semaglutide was open-label. DXA lean mass is not a direct measure of skeletal-muscle volume; lean-mass preservation does not establish improved function.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-026-04204-0